Takeda Announces Partnership with BIRAC in India to Foster Healthcare Innovation

• The local-to-global initiative will support healthcare innovation and technological advancement for comprehensive solutions catering to healthcare needs

• Besides supporting healthcare startups, the partnership will also contribute to India’s aspiration of emerging as a US$300 billion Bio-economy by 2030

Takeda today announced the signing of a three-year MoU with the Biotechnology Industry Research Assistance Council (BIRAC) (birac.nic.in), a public sector enterprise set up by the Department of Biotechnology, Government of India. The MoU was announced in the presence of Dr. Jitendra Singh, Hon’ble Union Minister of State for Science & Technology, Minister of State for the Prime Minister Office, Government of India, and senior government and industry leaders. The partnership will allow Takeda to extend advisory and mentoring support to innovators and entrepreneurs while assisting them from ideation to market deployment of new-age healthcare solutions. The collaboration resonates with BIRAC’s vision to stimulate, foster and enhance the strategic research and innovation capabilities of the Indian biotech industry for creation of affordable products addressing the needs of the largest section of society.

Speaking of the collaboration, Sanjay Patel, Global Head of Data Digital and Technology Innovation Capability Solutions, Takeda Pharmaceuticals International AG, said, “India is a vibrant and promising healthcare market. The country’s healthcare segment offers an incredible opportunity both for innovation and growth. The entrepreneurial spirit of domestic healthcare startups has the power to drive healthcare advancements not only in India but globally. This partnership between Takeda and BIRAC, thus, moves beyond convention, signifying a promise to further healthcare in a manner that sets the stage for lasting improvements in the years to come.“

Serina Fischer, General Manager, Takeda Biopharmaceuticals IndiaPvt. Ltd. said, “At Takeda, we are committed to meeting the unmet needs of patients by discovering and delivering life-transforming treatments and innovative solutions. Our vision and mission align with the Indian Government’s aspiration for local solutions to global healthcare challenges. This partnership serves as a practical blueprint, highlighting how public and private players can join forces to propel substantial and enduring advances in healthcare.“

Ruchi Sogarwal, Head of Corporate Affairs, Takeda Biopharmaceuticals India Pvt. Ltd., added, “Collaborations between the government, academia and industry contribute immensely to accelerating innovation and building disruptive healthcare technology solutions for addressing unmet patient needs. Our partnership with BIRAC will allow us to foster innovations, nurturing capabilities and enhancing global competitiveness translating bioscience into bioeconomy.”

The partnership was announced at the Global Bio-India (GBI) 2023 (www.globalbioindia.org) event organized by the Department of Biotechnology (DBT), Ministry of Science & Technology, Government of India and its Public Sector Undertaking, BIRAC. GBI is a mega international congregation of biotechnology stakeholders, including international bodies, regulatory bodies, Central and State Ministries, SMEs, large industries, bioclusters, research institutes, investors, and the startup ecosystem.

About Takeda

Takeda is focused on creating better health for people and a brighter future for the world. We aim to discover and deliver life-transforming treatments in our core therapeutic and business areas, including gastrointestinal and inflammation, rare diseases, plasma-derived therapies, oncology, neuroscience and vaccines. Together with our partners, we aim to improve the patient experience and advance a new frontier of treatment options through our dynamic and diverse pipeline. As a leading values-based, R&D-driven biopharmaceutical company headquartered in Japan, we are guided by our commitment to patients, our people and the planet. Our employees in approximately 80 countries and regions are driven by our purpose and are grounded in the values that have defined us for more than two centuries. For more information, visit www.takeda.com.

Important Notice

For the purposes of this notice, “press release” means this document, any oral presentation, any question and answer session and any written or oral material discussed or distributed by Takeda Pharmaceutical Company Limited (“Takeda”) regarding this release. This press release (including any oral briefing and any question-and-answer in connection with it) is not intended to, and does not constitute, represent or form part of any offer, invitation or solicitation of any offer to purchase, otherwise acquire, subscribe for, exchange, sell or otherwise dispose of, any securities or the solicitation of any vote or approval in any jurisdiction. No shares or other securities are being offered to the public by means of this press release. No offering of securities shall be made in the United States except pursuant to registration under the U.S. Securities Act of 1933, as amended, or an exemption therefrom. This press release is being given (together with any further information which may be provided to the recipient) on the condition that it is for use by the recipient for information purposes only (and not for the evaluation of any investment, acquisition, disposal or any other transaction). Any failure to comply with these restrictions may constitute a violation of applicable securities laws.

The companies in which Takeda directly and indirectly owns investments are separate entities. In this press release, “Takeda” is sometimes used for convenience where references are made to Takeda and its subsidiaries in general. Likewise, the words “we”, “us” and “our” are also used to refer to subsidiaries in general or to those who work for them. These expressions are also used where no useful purpose is served by identifying the particular company or companies.

Forward-Looking Statements

This press release and any materials distributed in connection with this press release may contain forward-looking statements, beliefs or opinions regarding Takeda’s future business, future position and results of operations, including estimates, forecasts, targets and plans for Takeda. Without limitation, forward-looking statements often include words such as “targets”, “plans”, “believes”, “hopes”, “continues”, “expects”, “aims”, “intends”, “ensures”, “will”, “may”, “should”, “would”, “could”, “anticipates”, “estimates”, “projects” or similar expressions or the negative thereof.

These forward-looking statements are based on assumptions about many important factors, including the following, which could cause actual results to differ materially from those expressed or implied by the forward-looking statements: the economic circumstances surrounding Takeda’s global business, including general economic conditions in Japan and the United States; competitive pressures and developments; changes to applicable laws and regulations, including global health care reforms; challenges inherent in new product development, including uncertainty of clinical success and decisions of regulatory authorities and the timing thereof; uncertainty of commercial success for new and existing products; manufacturing difficulties or delays; fluctuations in interest and currency exchange rates; claims or concerns regarding the safety or efficacy of marketed products or product candidates; the impact of health crises, like the novel coronavirus pandemic, on Takeda and its customers and suppliers, including foreign governments in countries in which Takeda operates, or on other facets of its business; the timing and impact of post-merger integration efforts with acquired companies; the ability to divest assets that are not core to Takeda’s operations and the timing of any such divestment(s); and other factors identified in Takeda’s most recent Annual Report on Form 20-F and Takeda’s other reports filed with the U.S. Securities and Exchange Commission, available on Takeda’s website at: https://www.takeda.com/investors/sec-filings-and-security-reports/ or at www.sec.gov. Takeda does not undertake to update any of the forward-looking statements contained in this press release or any other forward-looking statements it may make, except as required by law or stock exchange rule. Past performance is not an indicator of future results and the results or statements of Takeda in this press release may not be indicative of, and are not an estimate, forecast, guarantee or projection of Takeda’s future results.

Medical Information This press release contains information about products that may not be available in all countries, or may be available under different trademarks, for different indications, in different dosages, or in different strengths. Nothing contained herein should be considered a solicitation, promotion or advertisement for any prescription drugs including the ones under development.